Hib-DTaP-hepatitis B-poliovirus vaccine - GlaxoSmithKline

Drug Profile

Hib-DTaP-hepatitis B-poliovirus vaccine - GlaxoSmithKline

Alternative Names: DTPa-HBV-IPV/Hib Vaccine; DTPa-IPV/Hib; DTPw-HBV-IPV/Hib vaccine; GSK 2036874A; GSK 21774; GSK217744; Hexavalent combination vaccine - GlaxoSmithKline; Hib-DTP-acellular-hepatitis B-poliovirus vaccine - GlaxoSmithKline; Infanrix HepB-IPV/Hib; Infanrix HeXa; Infanrix®-IPV/Hib

Latest Information Update: 28 Oct 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Haemophilus vaccines; Hepatitis B vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 02 May 2017 GlaxoSmithKline plans a phase III trial for Tetanus, Poliomyelitis, Pertussis, Hepatitis B, Haemophilus infections and Diphtheria (Prevention, In infants) in India (IM) (NCT03128489)
  • 01 Sep 2016 Phase-III clinical trials in Tetanus, Poliomyelitis, Pertussis, Hepatitis B, Haemophilus infections and Diphtheria (Prevention, In infants) in Russia (IM) (NCT02858440)
  • 03 Aug 2016 GlaxoSmithKline plans a phase III trial for Tetanus, Poliomyelitis, Pertussis, Hepatitis B, Haemophilus infections and Diphtheria (Prevention, In infants) in Russia (IM) (NCT02858440)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top